Huľová S, Aziri R, Chovanec M, Mardiak J, Mego M, Pinďák D
Klin Onkol. 2019 Spring;32(2):129-132. doi: 10.14735/amko2019129.
Growing teratoma syndrome (GTS) is an uncommon clinical finding in patients treated for testicular cancer. It is diagnosed during or after chemotherapy as an expanding tumour mass not responding to the treatment while the serum tumour markers are within the normal range. Pathological evaluation of resected tissue confirms the structures of benign mature teratoma.
Authors report a case of metastatic germ cell testicular cancer treated with 2 lines of chemotherapy and everolimus, that had finally been subjected for the resection of voluminous metastatic masses. We give a brief overview of current records concerning clinical management of GTS, and support the major role of surgical treatment in GTS.
Patient with metastatic mixed germ cell tumour of testis underwent a radical orchiectomy and completed the 1st line treatment with BEP (bleomycin, etoposide, cisplatin) regimen. Radiographic restaging showed considerable disease progression to the retroperitoneum and supraclavicular lymph nodes. Second-line treatment with VIP (etoposide, ifosfamide, cisplatin) did not reverse the progression and the patient was consulted at our institute. Following the enrolment to the clinical study with everolimus, the patient exhibited continual metastatic growth in contrast to serum markers decrease. GTS was confirmed after resection of enormous retroperitoneal tumour mass, as well as from the specimen obtained from the subsequent supraclavicular and hepatal metastasectomy. The patient attained complete remission and has been closely observed over the last 31 months since the last surgery.
GTS is resistant to chemotherapy and radiation and complete surgical resection results in excellent disease control. Clinicians should be aware of this infrequent presentation of testicular tumours, to ensure the timely diagnosis and the appropriate surgical removal without any delay. Despite the great extent and vital vasculature encasement, surgery may be feasible and successful, as we report in our case, consistently with the published data.
成熟性畸胎瘤综合征(GTS)是睾丸癌患者中一种不常见的临床表现。它在化疗期间或化疗后被诊断为肿瘤肿块不断增大且对治疗无反应,而血清肿瘤标志物在正常范围内。切除组织的病理评估证实为良性成熟畸胎瘤结构。
作者报告一例转移性生殖细胞睾丸癌患者,接受了两线化疗和依维莫司治疗,最终接受了大量转移性肿块的切除术。我们简要概述了目前关于GTS临床管理的记录,并支持手术治疗在GTS中的主要作用。
一名睾丸转移性混合生殖细胞肿瘤患者接受了根治性睾丸切除术,并完成了BEP(博来霉素、依托泊苷、顺铂)方案的一线治疗。影像学重新分期显示疾病显著进展至腹膜后和锁骨上淋巴结。二线VIP(依托泊苷、异环磷酰胺、顺铂)治疗未能逆转疾病进展,该患者前来我院咨询。在入组依维莫司临床研究后,患者出现持续的转移灶生长,而血清标志物下降。在切除巨大的腹膜后肿瘤肿块以及随后从锁骨上和肝转移灶切除术中获取的标本后,确诊为GTS。患者实现了完全缓解,自上次手术以来的最后31个月里一直密切观察。
GTS对化疗和放疗耐药,完整的手术切除可实现良好的疾病控制。临床医生应了解这种罕见的睾丸肿瘤表现,以确保及时诊断并立即进行适当的手术切除。尽管肿瘤范围大且重要血管被包裹,但正如我们在病例中所报告的,与已发表的数据一致,手术可能是可行且成功的。